Biovica International AB (publ)

Stockholm Stock Exchange BIOVIC-B.ST

Biovica International AB (publ) Gross Profit for the year ending April 30, 2024: USD 622.37 K

Biovica International AB (publ) Gross Profit is USD 622.37 K for the year ending April 30, 2024, a 38.83% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Biovica International AB (publ) Gross Profit for the year ending April 30, 2023 was USD 448.31 K, a -5.25% change year over year.
Biovica International AB (publ) Gross Profit for the year ending April 30, 2022 was USD 473.13 K, a -23.66% change year over year.
Biovica International AB (publ) Gross Profit for the year ending April 30, 2021 was USD 619.75 K, a -28.47% change year over year.
Biovica International AB (publ) Gross Profit for the year ending April 30, 2020 was USD 866.42 K, a -4.37% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Stockholm Stock Exchange: BIOVIC-B.ST

Biovica International AB (publ)

CEO	Mr. Anders Rylander
IPO Date	March 29, 2017
Location	Sweden
Headquarters	Dag HammarskjOelds vAeg 54B
Employees	27
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Key trends

Past 5 years